Ani Pharmaceuticals (ANIP) Free Cash Flow Growth (1y) (2011 - 2026)
Ani Pharmaceuticals (ANIP) Free Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.33 Bn | 2.15 Bn | 134.35% |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 17.21% |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | -37.45% |
| 5 | United Therapeutics | 22.15 Bn | 19.48 Bn | 683.80 Mn | 58.76% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 97.24% |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | 43.69% |
| 8 | Elanco Animal Health | 11.74 Bn | 11.21 Bn | 798.00 Mn | 35.56% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Ani Pharmaceuticals | 1.63 Bn | 1.27 Bn | 165.89 Mn | -25.33% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -25.33% |
| Mar 31, 2026 | 53.97% |
| Dec 31, 2025 | 43.65% |
| Sep 30, 2025 | 15,080.80% |
| Jun 30, 2025 | 313.36% |
| Mar 31, 2025 | 99.27% |
| Dec 31, 2024 | -34.68% |
| Sep 30, 2024 | -99.32% |
| Jun 30, 2024 | -6.11% |
| Mar 31, 2024 | -10.63% |
| Dec 31, 2023 | 1,060.82% |
| Sep 30, 2023 | 775.94% |
| Jun 30, 2023 | 250.92% |
| Mar 31, 2023 | 199.37% |
| Dec 31, 2022 | 62.24% |
| Sep 30, 2022 | 210.47% |
| Jun 30, 2022 | -1,638.06% |
| Mar 31, 2022 | -196.12% |
| Dec 31, 2021 | -57.42% |
| Sep 30, 2021 | 30.63% |